The LIMCR

The LIMCR (Laboratory for Immunological and Molecular Cancer Research), which is integrated in the Third Medical Department of the Paracelsus Medical University Hospital, opened its doors in 2005 and has its research focus on chronic lymphocytic leukemia (CLL), myelodysplastic syndromes (MDS) and acut myeloid leukemia (AML). The LIMCR maintains a close connection with the clinic to ensure maximum synergy and efficacy in cancer therapy.

 

Click here to read more

Research Groups

 Murine-Lymphoma Models

Group leader: PD Dr. Alexander Egle

“The complexity of the disease can be mimicked in the murine model. In this system we are analyzing the effect of novel therapy concepts and the communication of leukemic cells with the immune system.” More

 Tumor immunology

Group leader: Dr. Roland Geisberger

“Leukemic cells benefit from deactivating other immune cells. We study the underlying mechanisms and search for ways to reactivate the immune system to combat leukemia.” More

 Microenvironment

Group leader: Assoc. Prof. Dr. Tanja Hartmann

“Leukemia cells are strongly dependent on the lymphoid tumor microenvironment, where they receive proliferative and pro-survival signals. We are interested in how CLL cells localize adjacent to these supportive signals.”More

 Immuno-oncology

Group leader: Dr. Nadja Zaborsky

“In principle, the cells of the immune system (NK cells, T cells) are able to combat cancer. However, cancer cells developed mechanisms for immune escape, which enables unhindered tumor growth. Immune therapies aim at reinvigorating the body’s own immune system to improve cancer treatment. In our working group, we are analyzing the interplay between genetic changes in cancer cells and alterations in immune cell composition and functionality, which is important to improve current immune therapy approaches.”

News

REGISTER NOW 05.-06.04.2019

5th International CCS Workshop and 15th International CLL Workshop Salzburg 2019

2019 SAVE THE DATE

3. Salzburg Breast Cancer Talk

Program

01.-02. März 2019

Organization:

Univ.Prof. Dr. Richard Greil, OA Dr. Simon Gampenrieder, OA Dr. Gabriel Rinnerthaler

Salzburg Cancer Research Institute (SCRI) with

Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)
in cooperation with the Cancer Cluster Salzburg and AGMT gemeinnützige GmbH

more